Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors
US-2016137650-A1 · May 19, 2016 · US
Therapeutic agent for fibrosis
US10695340B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10695340-B2 |
| Application number | US-201916573362-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 17, 2019 |
| Priority date | Jun 25, 2015 |
| Publication date | Jun 30, 2020 |
| Grant date | Jun 30, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided are a therapeutic agent and a pharmaceutical composition exerting an excellent prophylactic or therapeutic effect on fibrosis and symptoms associated with fibrosis. The therapeutic agent for fibrosis comprises 4-[2-fluoro-4-[[[(2-phenylacetyl)amino]thioxomethyl]amino]-phenoxy]-7-methoxy-N-methyl-6-quinolinecarboxamide or a salt thereof as an active ingredient.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating fibrosis scleroderma, comprising: administering 4-[2-fluoro-4-[[[(2-phenylacetyl)amino]thioxomethyl]amino]-phenoxy]-7-methoxy-N-methyl-6-quinolinecarboxamide or a salt thereof to a patient. 2. The method of claim 1 , wherein the scleroderma is disseminated scleroderma. 3. The method of claim 1 , wherein the scleroderma is focal scleroderma. 4. The method of claim 1 , wherein the 4-[2-fluoro-4-[[[(2-phenylacetyl)amino]thioxomethyl]amino]-phenoxy]-7-methoxy-N-methyl-6-quinolinecarboxamide or a salt thereof is orally administered to the patient. 5. The method of claim 1 , wherein the salt is a methanesulfonate salt. 6. The method of claim 1 , wherein the salt is a monomethanesulfonate salt. 7. The method of claim 1 , wherein 0.005 to 5,000 mg of the 4-[2-fluoro-4-[[[(2-phenylacetyl)amino]thioxomethyl]amino]-phenoxy]-7-methoxy-N-methyl-6-quinolinecarboxamide or a salt thereof is administered to the patient. 8. The method of claim 1 , wherein 0.01 to 1,000 mg of the 4-[2-fluoro-4-[[[(2-phenylacetyl)amino]thioxomethyl]amino]-phenoxy]-7-methoxy-N-methyl-6-quinolinecarboxamide or a salt thereof is administered to the patient.
Assignees
Inventors
Classifications
attached in position 4 · CPC title
- A61K31/47Primary
Quinolines; Isoquinolines · CPC title
Drugs for disorders of the respiratory system · CPC title
Drugs for dermatological disorders · CPC title
of the kidneys · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10695340B2 cover?
- Provided are a therapeutic agent and a pharmaceutical composition exerting an excellent prophylactic or therapeutic effect on fibrosis and symptoms associated with fibrosis. The therapeutic agent for fibrosis comprises 4-[2-fluoro-4-[[[(2-phenylacetyl)amino]thioxomethyl]amino]-phenoxy]-7-methoxy-N-methyl-6-quinolinecarboxamide or a salt thereof as an active ingredient.
- Who is the assignee on this patent?
- Taiho Pharmaceutical Co Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K31/47. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 30 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).